Acumen Pharmaceuticals, Inc. (ABOS)
NASDAQ: ABOS · Real-Time Price · USD
1.070
+0.030 (2.88%)
Jun 4, 2025, 4:00 PM - Market closed
Acumen Pharmaceuticals Stock Forecast
ABOS's stock price has decreased by -61.09% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
According to 3 professional analysts, the 12-month price target for Acumen Pharmaceuticals stock ranges from a low of $4.00 to a high of $11. The average analyst price target of $7.33 forecasts a 585.05% increase in the stock price over the next year.
Price Target: $7.33 (+585.05%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 28, 2025.
Analyst Ratings
The average analyst rating for Acumen Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 3 | 3 | 3 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| UBS | UBS | Strong Buy Maintains $6 → $4 | Strong Buy | Maintains | $6 → $4 | +273.83% | Mar 28, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $15 → $11 | Strong Buy | Maintains | $15 → $11 | +928.04% | Mar 28, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +1,301.87% | Nov 13, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +1,301.87% | Oct 3, 2024 |
| UBS | UBS | Strong Buy Maintains $14 → $6 | Strong Buy | Maintains | $14 → $6 | +460.75% | Aug 15, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-2.17
from -1.71
EPS Next Year
-1.72
from -2.17
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | n/a | n/a | ||
| Avg | n/a | n/a | n/a | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.93 | -0.91 | -1.35 | ||
| Avg | -2.17 | -1.72 | -1.82 | ||
| Low | -2.48 | -2.05 | -2.23 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.